CA Patent

CA2998504C — Sustained release olanzapine formulations

Assigned to Teva Pharmaceuticals International GmbH · Expires 2023-06-20 · 3y expired

What this patent protects

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutica…

USPTO Abstract

The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2998504C
Jurisdiction
CA
Classification
—
Expires
2023-06-20
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceuticals International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.